{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:49:22Z","timestamp":1769878162184,"version":"3.49.0"},"reference-count":110,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T00:00:00Z","timestamp":1625961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Understanding the risks of COVID-19 in patients with Multiple Sclerosis (MS) receiving disease-modifying therapies (DMTs) and their immune reactions is vital to analyze vaccine response dynamics. A systematic review on COVID-19 course and outcomes in patients receiving different DMTs was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Emerging data on SARS-CoV-2 vaccines was used to elaborate recommendations. Data from 4417 patients suggest that MS per se do not portend a higher risk of severe COVID-19. As for the general population, advanced age, comorbidities, and higher disability significantly impact COVID-19 outcomes. Most DMTs have a negligible influence on COVID-19 incidence and outcome, while for those causing severe lymphopenia and hypogammaglobulinemia, such as anti-CD20 therapies, there might be a tendency of increased hospitalization, worse outcomes and a higher risk of re-infection. Blunted immune responses have been reported for many DMTs, with vaccination implications. Clinical evidence does not support an increased risk of MS relapse or vaccination failure, but vaccination timing needs to be individually tailored. For cladribine and alemtuzumab, it is recommended to wait 3\u20136 months after the last cycle until vaccination. For the general anti-CD20 therapies, vaccination must be deferred toward the end of the cycle and the next dose administered at least 4\u20136 weeks after completing vaccination. Serological status after vaccination is highly encouraged. Growing clinical evidence and continuous surveillance are extremely important to continue guiding future treatment strategies and vaccination protocols.<\/jats:p>","DOI":"10.3390\/vaccines9070773","type":"journal-article","created":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T22:16:48Z","timestamp":1626041808000},"page":"773","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations"],"prefix":"10.3390","volume":"9","author":[{"given":"Ver\u00f3nica","family":"Cabreira","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Neurologia, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Departamento de Neuroci\u00eancias Cl\u00ednicas e Sa\u00fade Mental, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal"}]},{"given":"Pedro","family":"Abreu","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Departamento de Neuroci\u00eancias Cl\u00ednicas e Sa\u00fade Mental, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6878-8568","authenticated-orcid":false,"given":"Ricardo","family":"Soares-dos-Reis","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Departamento de Neuroci\u00eancias Cl\u00ednicas e Sa\u00fade Mental, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal"},{"name":"i3S-Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o da Universidade do Porto, 4200-135 Porto, Portugal"}]},{"given":"Joana","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Departamento de Neuroci\u00eancias Cl\u00ednicas e Sa\u00fade Mental, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal"}]},{"given":"Maria Jos\u00e9","family":"S\u00e1","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Faculdade de Ci\u00eancias da Sa\u00fade, Universidade Fernando Pessoa, 4249-004 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","article-title":"Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts","volume":"108","author":"Wang","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00430-020-00693-z","article-title":"Assessing SARS-CoV-2 RNA levels and lymphocyte\/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity","volume":"209","author":"Han","year":"2020","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10654-019-00595-2","article-title":"Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: A nationwide population-based registry study from Norway","volume":"35","author":"Ghaderi","year":"2020","journal-title":"Eur. J. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s13311-021-01008-7","article-title":"Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives","volume":"18","author":"Bhise","year":"2021","journal-title":"Neurotherapeutics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102195","DOI":"10.1016\/j.msard.2020.102195","article-title":"B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran","volume":"43","author":"Safavi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical Characteristics and Outcomes in Patients with Coronavirus Disease 2019 and Multiple Sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102196","DOI":"10.1016\/j.msard.2020.102196","article-title":"Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?","volume":"42","author":"Gemcioglu","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1212\/NXI.0000000000000783","article-title":"COVID-19 in MS: Initial observations from the Pacific Northwest","volume":"7","author":"Bowen","year":"2020","journal-title":"Neurol. Neuroimmunol. neuroinflammation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1212\/NXI.0000000000000835","article-title":"COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflammation."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102276","DOI":"10.1016\/j.msard.2020.102276","article-title":"Characteristics of COVID-19 disease in multiple sclerosis patients","volume":"45","author":"Barzegar","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102204","DOI":"10.1016\/j.msard.2020.102204","article-title":"COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile","volume":"42","author":"Ciampi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102453","DOI":"10.1016\/j.msard.2020.102453","article-title":"Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients","volume":"46","author":"Mantero","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102472","DOI":"10.1016\/j.msard.2020.102472","article-title":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","volume":"46","author":"Sahraian","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"117147","DOI":"10.1016\/j.jns.2020.117147","article-title":"COVID-19 in multiple sclerosis patients and risk factors for severe infection","volume":"418","author":"Chaudhry","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.medcli.2020.06.021","article-title":"Risk of SARS-CoV-2 infection and clinical outcomes in multiple sclerosis patients in La Rioja (Spain): Riesgo de infecci\u00f3n por SARS-CoV-2 y resultados cl\u00ednicos en pacientes con esclerosis m\u00faltiple en la Rioja (Espa\u00f1a)","volume":"155","year":"2020","journal-title":"Med. Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp-2020-324449","article-title":"Self-diagnosed COVID-19 in people with multiple sclerosis: A community-based cohort of the UK MS Register","volume":"92","author":"Evangelou","year":"2020","journal-title":"J. Neurol. Neurosurg. psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1177\/1352458520942198","article-title":"COVID-19 in multiple sclerosis: The Dutch experience","volume":"26","author":"Loonstra","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40263-021-00804-1","article-title":"COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies","volume":"35","author":"Reder","year":"2021","journal-title":"CNS Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zabalza, A., C\u00e1rdenas-Robledo, S., Tagliani, P., Arrambide, G., Otero-Romero, S., Carbonell-Mirabent, P., Rodriguez-Barranco, M., Rodr\u00edguez-Acevedo, B., Vera, J.L.R., and Resina-Salles, M. (2020). COVID-19 in multiple sclerosis patients: Susceptibility, severity risk factors and serological response. Eur. J. Neurol.","DOI":"10.1111\/ene.14690"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102886","DOI":"10.1016\/j.msard.2021.102886","article-title":"COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM","volume":"51","author":"Alonso","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_24","unstructured":"(2021). REDONE.br \u2013 Neuroimmunology Brazilian Study Group Focused on COVID-19 and MS. Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis. Mult. Scler."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Berger, J.R., Brandstadter, R., and Bar-Or, A. (2020). COVID-19 and MS disease-modifying therapies. Neurol. Neuroimmunol. Neuroinflammation, 7.","DOI":"10.1212\/NXI.0000000000000761"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Laroni, A., Schiavetti, I., Sormani, M.P., and Uccelli, A. (2020). COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. Mult. Scler.","DOI":"10.1177\/1352458520971817"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Stertz, S., and Hale, B.G. (2021). Interferon system deficiencies exacerbating severe pandemic virus infections. Trends Microbiol.","DOI":"10.1016\/j.tim.2021.03.001"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100287","DOI":"10.1016\/j.ensci.2020.100287","article-title":"A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies","volume":"21","author":"Kataria","year":"2020","journal-title":"Eneurologicalsci"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10072-020-04519-x","article-title":"Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: A multicenter European study","volume":"41","author":"Costa","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102338","DOI":"10.1016\/j.msard.2020.102338","article-title":"MSCOVID19: Using social media to achieve rapid dissemination of health information","volume":"45","author":"Nesbitt","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1007\/s00415-020-09944-8","article-title":"COVID-19 in teriflunomide-treated patients with multiple sclerosis","volume":"267","author":"Maghzi","year":"2020","journal-title":"J. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"577323","DOI":"10.1016\/j.jneuroim.2020.577323","article-title":"The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia","volume":"346","author":"Ciardi","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00415-020-10196-9","article-title":"Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis","volume":"268","author":"Mantero","year":"2020","journal-title":"J. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102372","DOI":"10.1016\/j.msard.2020.102372","article-title":"Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy","volume":"44","author":"Crescenzo","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1007\/s00415-020-09921-1","article-title":"Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse","volume":"267","author":"Saker","year":"2020","journal-title":"J. Neuro."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"117011","DOI":"10.1016\/j.jns.2020.117011","article-title":"Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide","volume":"416","author":"Bollo","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102734","DOI":"10.1016\/j.msard.2020.102734","article-title":"COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review","volume":"48","author":"Capone","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s10072-021-05097-2","article-title":"Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide","volume":"42","author":"Yetkin","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_40","first-page":"1","article-title":"COVID-19 in multiple sclerosis patients treated with dimethyl fumarate","volume":"Epub","author":"Capone","year":"2021","journal-title":"J. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00415-020-10015-1","article-title":"COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis","volume":"268","author":"Mantero","year":"2020","journal-title":"J. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"102073","DOI":"10.1016\/j.msard.2020.102073","article-title":"The COVID-19 pandemic and the use of MS disease-modifying therapies","volume":"39","author":"Giovannoni","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Barzegar, M., Mirmosayyeb, O., Nehzat, N., Sarrafi, R., Khorvash, F., Maghzi, A.-H., and Shaygannejad, V. (2020). COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol. Neuroimmunol. neuroinflammation, 7.","DOI":"10.1212\/NXI.0000000000000753"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"102182","DOI":"10.1016\/j.msard.2020.102182","article-title":"A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19","volume":"42","author":"Wingerchuk","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102180","DOI":"10.1016\/j.msard.2020.102180","article-title":"Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod","volume":"42","author":"Foerch","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"577282","DOI":"10.1016\/j.jneuroim.2020.577282","article-title":"Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection","volume":"345","author":"Chiarini","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/jmv.26279","article-title":"Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal","volume":"93","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102414","DOI":"10.1016\/j.msard.2020.102414","article-title":"Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod","volume":"45","author":"Mallucci","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_49","first-page":"102314","article-title":"Mild COVID-19 Infection in a Patient with Multiple Sclerosis, while Taking Fingolimod: A Case Report","volume":"44","author":"Mohammadpour","year":"2021","journal-title":"J. Neurol. Neurosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"102165","DOI":"10.1016\/j.msard.2020.102165","article-title":"COVID-19 occurring during Natalizumab treatment: A case report in a patient with extended interval dosing approach","volume":"41","author":"Borriello","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"102250","DOI":"10.1016\/j.msard.2020.102250","article-title":"Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?","volume":"44","author":"Aguirre","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Rimmer, K., Farber, R., Thakur, K., Braverman, G., Podolsky, D., Sutherland, L., Migliore, C., Ryu, Y.K., Levin, S., and De Jager, P.L. (2020). Fatal COVID-19 in an MS patient on natalizumab: A case report. Mult. Scler. J. Exp. Transl. Clin., 6.","DOI":"10.1177\/2055217320942931"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"102222","DOI":"10.1016\/j.msard.2020.102222","article-title":"Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic","volume":"43","author":"Ghajarzadeh","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"102185","DOI":"10.1016\/j.msard.2020.102185","article-title":"Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain","volume":"42","author":"Pytel","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"102201","DOI":"10.1016\/j.msard.2020.102201","article-title":"Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab","volume":"42","author":"Suwanwongse","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"102120","DOI":"10.1016\/j.msard.2020.102120","article-title":"COVID-19 in a MS patient treated with ocrelizumab: Does immunosuppression have a protective role?","volume":"42","author":"Novi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"102192","DOI":"10.1016\/j.msard.2020.102192","article-title":"COVID-19 in persons with multiple sclerosis treated with ocrelizumab\u2014A pharmacovigilance case series","volume":"42","author":"Hughes","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"102725","DOI":"10.1016\/j.msard.2020.102725","article-title":"COVID-19 in ocrelizumab-treated people with multiple sclerosis","volume":"49","author":"Hughes","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"102306","DOI":"10.1016\/j.msard.2020.102306","article-title":"COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies","volume":"44","author":"Aguirre","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"102315","DOI":"10.1016\/j.msard.2020.102315","article-title":"Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia","volume":"44","author":"Conte","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"102323","DOI":"10.1016\/j.msard.2020.102323","article-title":"Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report","volume":"44","author":"Lucchini","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"102341","DOI":"10.1016\/j.msard.2020.102341","article-title":"Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab","volume":"44","author":"Thornton","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"102442","DOI":"10.1016\/j.msard.2020.102442","article-title":"Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab","volume":"45","author":"Iannetta","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s10072-020-04522-2","article-title":"Coronavirus disease 2019: Favorable outcome in an immunosuppressed patient with multiple sclerosis","volume":"41","author":"Devogelaere","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00415-020-10046-8","article-title":"Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients","volume":"268","author":"Woo","year":"2021","journal-title":"J. Neuro."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458520943791","article-title":"Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient","volume":"26","author":"Wurm","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/acn3.51342","article-title":"Multiple sclerosis, rituximab, and COVID-19","volume":"8","author":"Smith","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"102922","DOI":"10.1016\/j.msard.2021.102922","article-title":"Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis","volume":"52","author":"Bose","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/pai.13263","article-title":"Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover","volume":"31","author":"Soresina","year":"2020","journal-title":"Pediatric allergy. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"102777","DOI":"10.1016\/j.msard.2021.102777","article-title":"Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab","volume":"49","author":"Hernandez","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Anne, H., Cross, S.D., Habek, M., Davydovskaya, M., Totolyan, N., Pingili, R., Mancione, L., Sullivan, R., Zalesak, M., and Su, W. (2021). Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab. Neurology, 96.","DOI":"10.1212\/WNL.96.15_supplement.4123"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ana.25770","article-title":"SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad","volume":"87","author":"Amor","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/1352458520926459","article-title":"Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression","volume":"26","author":"Carandini","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"102297","DOI":"10.1016\/j.msard.2020.102297","article-title":"Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab","volume":"44","author":"Pytel","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"102314","DOI":"10.1016\/j.msard.2020.102314","article-title":"Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab","volume":"44","author":"Guevara","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102402","DOI":"10.1016\/j.msard.2020.102402","article-title":"COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab","volume":"45","author":"Palao","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"102447","DOI":"10.1016\/j.msard.2020.102447","article-title":"COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID","volume":"46","author":"Fiorella","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"102908","DOI":"10.1016\/j.msard.2021.102908","article-title":"Alemtuzumab in Covid era","volume":"51","author":"Iovino","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1177\/1352458520943783","article-title":"COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment","volume":"26","author":"Dersch","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.msard.2020.102452","article-title":"Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice","volume":"45","author":"Petracca","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1016\/j.msard.2020.102476","article-title":"Normal antibody response after COVID-19 during treatment with cladribine","volume":"46","author":"Celius","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"102469","DOI":"10.1016\/j.msard.2020.102469","article-title":"Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets","volume":"46","author":"Jack","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"102929","DOI":"10.1016\/j.msard.2021.102929","article-title":"COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update","volume":"51","author":"Jack","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_84","first-page":"1","article-title":"COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: A monocentric experience","volume":"Epub","author":"Preziosa","year":"2020","journal-title":"J. Neurol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"102775","DOI":"10.1016\/j.msard.2021.102775","article-title":"COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?","volume":"49","author":"Gelibter","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"n523","DOI":"10.1136\/bmj.n523","article-title":"Covid-19: First doses of vaccines in Scotland led to a substantial fall in hospital admissions","volume":"372","author":"Torjesen","year":"2021","journal-title":"BMJ"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.13495","article-title":"COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases","volume":"202","author":"Baker","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"102880","DOI":"10.1016\/j.msard.2021.102880","article-title":"Willingness to be vaccinated against COVID-19: An exploratory online survey in a Portuguese cohort of multiple sclerosis patients","volume":"51","author":"Serrazina","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"102788","DOI":"10.1016\/j.msard.2021.102788","article-title":"Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States","volume":"49","author":"Ehde","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"102439","DOI":"10.1016\/j.msard.2020.102439","article-title":"Effects of MS disease-modifying therapies on responses to vaccinations: A review","volume":"45","author":"Ciotti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Achiron, A., Dolev, M., Menascu, S., Zohar, D.-N., Dreyer-Alster, S., Miron, S., Shirbint, E., Magalashvili, D., Flechter, S., and Givon, U. (2021). COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult. Scler.","DOI":"10.1177\/13524585211003476"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41582-020-0385-8","article-title":"Neurological immunotherapy in the era of COVID-19\u2014Looking for consensus in the literature","volume":"16","author":"Korsukewitz","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1212\/NXI.0000000000000409","article-title":"Immune response to vaccines is maintained in patients treated with dimethyl fumarate","volume":"5","author":"Howard","year":"2018","journal-title":"Neurol. Neuroimmunol. neuroinflammation"},{"key":"ref_101","first-page":"e1999","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study","volume":"95","author":"Calkwood","year":"2020","journal-title":"Neurology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"102983","DOI":"10.1016\/j.msard.2021.102983","article-title":"COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab","volume":"52","author":"Buttari","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Khayat-Khoei, M., Conway, S., Rubinson, D.A., Jarolim, P., and Houtchens, M.K. (2021). Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab. J. Neurol.","DOI":"10.1007\/s00415-021-10463-3"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Chilimuri, S., Mantri, N., Gongati, S., Zahid, M., and Sun, H. (2021). COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab. Vaccines, 9.","DOI":"10.3390\/vaccines9030219"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S1473-3099(20)30764-7","article-title":"Genomic evidence for reinfection with SARS-CoV-2: A case study","volume":"21","author":"Tillett","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458510391344","article-title":"Safety and tolerability of cladribine tablets in multiple sclerosis: The CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study","volume":"17","author":"Cook","year":"2011","journal-title":"Mult. Scler."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/1352458520952310","article-title":"Vaccinations in patients with multiple sclerosis: A Delphi consensus statement","volume":"27","author":"Riva","year":"2021","journal-title":"Mult. Scler."},{"key":"ref_108","first-page":"99","article-title":"Multiple Sclerosis and SARS-CoV-2","volume":"9","author":"Sellner","year":"2021","journal-title":"Vaccination"},{"key":"ref_109","unstructured":"Ilya Kister, K.M., Mulligan, M.J., Patskovsky, Y., Voloshyna Ferstler, N., Zhavtis Ryerson, L., Curtin, R., Kim, J., Tardio, E., Rimier, Z., and Silverman, G.J. (2021, January 18). Preliminary results of Ongoing, prospective study of antibody and T-cell responses to SARS-CoV-2 in patients with MS on ocrelizumab and other disease-modifying therapies. Proceedings of the American Academy of Neurology (AAN) 2021 Annual Meeting Emerging Science Session, Virtual."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/practneurol-2020-002527","article-title":"Protecting people with multiple sclerosis through vaccination","volume":"20","author":"Reyes","year":"2020","journal-title":"Pract. Neurol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/7\/773\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:28:58Z","timestamp":1760164138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/7\/773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,11]]},"references-count":110,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["vaccines9070773"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9070773","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,11]]}}}